Mutation accumulation in cancer genes relates to nonoptimal outcome in chronic myeloid leukemia

Show full item record



Permalink

http://hdl.handle.net/10138/313020

Citation

Awad , S A , Kankainen , M , Ojala , T , Koskenvesa , P , Eldfors , S , Ghimire , B , Kumar , A , Kytölä , S , Kamel , M M , Heckman , C A , Porkka , K & Mustjoki , S 2020 , ' Mutation accumulation in cancer genes relates to nonoptimal outcome in chronic myeloid leukemia ' , Blood advances , vol. 4 , no. 3 , pp. 546-559 . https://doi.org/10.1182/bloodadvances.2019000943

Title: Mutation accumulation in cancer genes relates to nonoptimal outcome in chronic myeloid leukemia
Author: Awad, Shady Adnan; Kankainen, Matti; Ojala, Teija; Koskenvesa, Perttu; Eldfors, Samuli; Ghimire, Bishwa; Kumar, Ashwini; Kytölä, Soili; Kamel, Mahmoud M.; Heckman, Caroline A.; Porkka, Kimmo; Mustjoki, Satu
Contributor: University of Helsinki, Department of Clinical Chemistry and Hematology
University of Helsinki, HUSLAB
University of Helsinki, Department of Pharmacology
University of Helsinki, HUS Comprehensive Cancer Center
University of Helsinki, Institute for Molecular Medicine Finland
University of Helsinki, Institute for Molecular Medicine Finland
University of Helsinki, Institute for Molecular Medicine Finland
University of Helsinki, HUSLAB
University of Helsinki, Research Programs Unit
University of Helsinki, HUS Comprehensive Cancer Center
University of Helsinki, HUS Comprehensive Cancer Center
Date: 2020-02-11
Language: eng
Number of pages: 14
Belongs to series: Blood advances
ISSN: 2473-9529
URI: http://hdl.handle.net/10138/313020
Abstract: Chronic myeloid leukemia (CML) is a myeloproliferative neoplasm accounting for similar to 15% of all leukemia. Progress of the disease from an indolent chronic phase to the more aggressive accelerated phase or blast phase (BP) occurs in a minority of cases and is associated with an accumulation of somatic mutations. We performed genetic profiling of 85 samples and transcriptome profiling of 12 samples from 59 CML patients. We identified recurrent somatic mutations in ABL1 (37%), ASXL1 (26%), RUNX1 (16%), and BCOR (16%) in the BP and observed that mutation signatures in the BP resembled those of acute myeloid leukemia (AML). We found that mutation load differed between the indolent and aggressive phases and that nonoptimal responders had more nonsilent mutations than did optimal responders at the time of diagnosis, as well as in follow-up. Using RNA sequencing, we identified other than BCR-ABL1 cancer-associated hybrid genes in 6 of the 7 BP samples. Uncovered expression alterations were in turn associated with mechanisms and pathways that could be targeted in CML management and by which somatic alterations may emerge in CML. Last, we showed the value of genetic data in CML management in a personalized medicine setting.
Subject: PROTEIN-TYROSINE PHOSPHATASES
DNA-DAMAGE RESPONSE
MISMATCH REPAIR
STEM
REACTIVATION
EXPRESSION
CELLS
RECOMBINATION
SIGNATURES
NEOPLASMS
3122 Cancers
Rights:


Files in this item

Total number of downloads: Loading...

Files Size Format View
advancesadv2019000943.pdf 1.518Mb PDF View/Open

This item appears in the following Collection(s)

Show full item record